Chiral inversion and enantioselective active metabolite formation of prasugrel, a novel thienopyridine antiplatelet agent, in dogs

被引：0
|
作者：
Takahashi, Makoto
Kawabata, Kiyoshi
Kurihara, Atsushi
Ikeda, Toshihiko
Sone, Junko
Farid, Nagy A.
机构：
[1] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo 140, Japan
[2] Sankyo Co Ltd, Core Technol Res Labs, Tokyo 140, Japan
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
DRUG METABOLISM REVIEWS | 2006年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
141
引用
收藏
页码：88 / 89
页数：2
相关论文
共 50 条
  • [31] Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
    Niitsu, Y
    Jakubowski, JA
    Sugidachi, A
    Asai, F
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02): : 184 - 194
  • [32] A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma
    Mazzucchelli, Iolanda
    Franco, Valentina
    Fattore, Cinzia
    Marchiselli, Roberto
    Perucca, Emilio
    Gatti, Giuliana
    THERAPEUTIC DRUG MONITORING, 2007, 29 (03) : 319 - 324
  • [33] Biosynthesis of 5-oxo-ETE and formation of a novel biologically active metabolite, fog7.
    Murphy, RC
    Bowers, RC
    Hevko, J
    Zarini, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U94 - U94
  • [34] Enantioselective Transition-Metal Catalyzed Carbon–Carbon Bond Formation Reactions using Novel Chiral Ferrocenes and Cyclophanes
    Xue Long Hou
    Shu Li You
    Tao Tu
    Wei Ping Deng
    Xun Wei Wu
    Ming Li
    Ke Yuan
    Tang Zhi Zhang
    Li Xin Dai
    Topics in Catalysis, 2005, 35 : 87 - 103
  • [35] Enantioselective mannich-type reactions using a novel chiral zirconium catalyst for the synthesis of optically active β-amino acid derivatives
    Ishitani, H
    Ueno, M
    Kobayashi, S
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (34) : 8180 - 8186
  • [36] Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans
    Grindel, JM
    Jaworski, T
    Piraner, O
    Emanuele, RM
    Balasubramanian, M
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (09) : 1936 - 1947
  • [37] Enantioselective transition-metal catalyzed carbon-carbon bond formation reactions using novel chiral ferrocenes and cyclophanes
    Hou, XL
    You, SL
    Tu, T
    Deng, WP
    Wu, XW
    Li, M
    Yuan, K
    Zhang, TZ
    Dai, LX
    TOPICS IN CATALYSIS, 2005, 35 (1-2) : 87 - 103
  • [38] Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs - Evidence for the formation of novel glutathione and two cysteine conjugates
    Kitani, M
    Miyamoto, G
    Nagasawa, M
    Yamada, T
    Matsubara, J
    Uchida, M
    Odomi, M
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (06) : 663 - 674
  • [39] In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: A comparison with human liver microsomes
    Quintieri, Luigi
    Fantin, Marianna
    Palatini, Pietro
    De Martin, Sara
    Rosato, Antonio
    Caruso, Michele
    Geroni, Cristina
    Floreani, Maura
    BIOCHEMICAL PHARMACOLOGY, 2008, 76 (06) : 784 - 795
  • [40] Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022
    Shimazawa, M
    Takiguchi, Y
    Umemura, K
    Kondo, K
    Nakashima, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (2-3) : 183 - 189
12345